Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 62

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 62
---
 decrease was partially offset by an increase
of approximately $0.1 million in professional fees.

Other
Income, Net

During
the three months ended September 30, 2025, our other income, net was approximately $0.04 million, which represented a decrease of approximately
$0.03 million, or approximately 46.5%, compared to approximately $0.07 million for the three months ended September 30, 2024. The other
income generated in the period consists primarily of income earned on our cash and cash equivalent accounts, the balances of which were
lower during the three months ended September 30, 2025 compared to the three months ended September 30, 2024.

Nine
months ended September 30, 2025 compared to nine months ended September 30, 2024

The
following tables set forth our results of operations for the nine months ended September 30, 2025 and 2024 and the relative dollar change
between the two periods.

    Nine
    months ended

    September
    30,

    Change

    2025

    2024

    ($)

    %

    Operating
    expenses:

    Research
    and development
     
    $
    6,495,677

    $
    4,771,152

    $
    1,724,525

    36.1
    %
  
    General
    and administrative

    5,182,132

    6,423,029

    (1,240,897
    )

    (19.3
    )%

    Total
    operating expenses

    11,677,809

    11,194,181

    483,628

    4.3
    %

    Loss
    from operations

    (11,677,809
    )

    (11,194,181
    )

    (483,628
    )

    4.3
    %

    Other
    income, net

    94,764

    303,201

    (208,437
    )

    (68.7
    )%
  
    Change
    in fair value of convertible promissory notes

    (1,153,421
    )

    -

    (1,153,421
    )

    100
    % 

    Net
    loss
     
    $
    (12,